Registry of patients with antiphospholipid antibodies

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to create a comprehensive registry for patients who test positive for antiphospholipid antibodies. Utilizing a web-based application called REDCap, the study collects data on patient demographics, clinical characteristics, and laboratory results related to antiphospholipid syndrome. Eligible participants are adults aged 18 to 60 who have shown persistent positivity for specific antiphospholipid antibodies. Patients will be monitored annually for clinical updates and blood samples will be collected for further analysis.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* age between 18 and 60 years;
* persistent (at least 12 weeks apart) aPL-positivity within 12 months prior to screening

Exclusion Criteria:

* no inform consent
* impossible follow up
* pregnancy

Where it's running

• CHRU de Nancy
  Nancy, France Recruiting
• CHRU de Lille
  Lille, France Not yet recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Thrombocytopenia Trajectories in antiphospholipid syndrome

  This study tests whether patterns in platelet counts over time can predict outcomes for adults with antiphospholipid syndrome.

  Recruiting New Valley University · Al Khārjah, Kharga Oasis · NCT07757789

• BCT301 CAR-iT cell therapy for hard-to-treat autoimmune diseases

  This early‑phase study tests whether off-the-shelf BCT301 CAR-iT cells can be given safely to adults with refractory autoimmune diseases to see if they can be tolerated and what dose works best.

  Recruiting Early Phase 1 Peking University Third Hospital · Beijing · NCT07301164

• Characterization of Autoreactive B Cells in Autoimmune Diseases and Immune Deficiencies

  Researchers are testing to see how autoreactive B cells behave in people with autoimmune diseases or immune deficiencies to better understand how these cells may contribute to disease.

  Recruiting University Hospital, Strasbourg, France · Strasbourg · NCT07251179

• YTS109 cell therapy for relapsed or treatment‑resistant autoimmune diseases

  This will try a single infusion of YTS109 immune cells in adults 18–65 with relapsed or treatment‑resistant autoimmune diseases such as lupus, Sjogren’s, systemic sclerosis, inflammatory myopathies, or ANCA‑associated vasculitis.

  Recruiting at 2 sites Phase 1 China Immunotech (Beijing) Biotechnology Co., Ltd. · Xuzhou, Jiangsu and 1 other locations · NCT07236801

• YTS109 cell therapy for relapsed or refractory autoimmune diseases

  This will try a single infusion of YTS109 immune cells to see if they are safe and help adults 18–65 with relapsed or refractory lupus (including lupus nephritis), Sjogren's syndrome, inflammatory myopathy, or ANCA‑associated vasculitis.

  Recruiting Phase 1 China Immunotech (Beijing) Biotechnology Co., Ltd. · Bengbu · NCT07236762

• Antiphospholipid syndrome in people 65 and older who had an ischemic stroke

  This study will test whether routine blood testing for antiphospholipid antibodies in people aged 65 and over hospitalized with ischemic stroke or TIA can identify previously unrecognized antiphospholipid syndrome.

  Recruiting CHU de Reims · Reims · NCT07163338

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.